[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @BiotechPort FBCC FBCC posts on X about $immx, the first, $prax, at least the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::780646751963230208/interactions)  - X Week XXXXXX +5,978% - X Month XXXXXXX +23% - X Months XXXXXXX +1,661% - X Year XXXXXXX +4,814% ### Mentions: X [#](/creator/twitter::780646751963230208/posts_active)  - X Month XX -XX% - X Months XX +291% - X Year XXX +643% ### Followers: XXXXX [#](/creator/twitter::780646751963230208/followers)  - X Week XXXXX +2% - X Month XXXXX +3.40% - X Months XXXXX +20% - X Year XXXXX +24% ### CreatorRank: XXXXXXX [#](/creator/twitter::780646751963230208/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) X% **Social topic influence** [$immx](/topic/$immx) #5, [the first](/topic/the-first) 10%, [$prax](/topic/$prax) 10%, [at least](/topic/at-least) 10%, [$kymr](/topic/$kymr) 5%, [$9b](/topic/$9b) 5%, [ceo](/topic/ceo) 5%, [the original](/topic/the-original) 5%, [business](/topic/business) 5%, [$capr](/topic/$capr) X% **Top accounts mentioned or mentioned by** [@deepsouthdoctor](/creator/undefined) [@sanctuarybio](/creator/undefined) [@monaco_biotech](/creator/undefined) [@ciubsandwich070](/creator/undefined) [@sanctuary_bio](/creator/undefined) **Top assets mentioned** [Praxis Precision Medicines, Inc. Common Stock (PRAX)](/topic/$prax) [Kymera Therapeutics, Inc. Common Stock (KYMR)](/topic/$kymr) [Terns Pharmaceuticals, Inc. Common Stock (TERN)](/topic/$tern) [AbbVie Inc (ABBV)](/topic/$abbv) [Wave Life Sciences Ltd. Ordinary Shares (WVE)](/topic/$wve) ### Top Social Posts Top posts by engagements in the last XX hours "$IMMX It is possible we are seeing emergence of a functional cure for this nasty sever disease. Sure first it will go for the r/r patients but whoever will buy them out can move to the first. Patients can be cure directly after the diagnosis without the need of taking chronic drugs for years and preventing any continuation of slow deterioration of the organs. Also just secured a nice pipe. Supper cheap here. $150MM EV" [X Link](https://x.com/BiotechPort/status/1997810466798649516) 2025-12-07T23:28Z 3619 followers, 5279 engagements "$IMMX "One and done treatment" according to the KOL. CRS Gr 1-2 (majority Gr1) 1d duration. No Neurological side effects. Some patients are in CR more than 12m The X in VGPR are on their way to get to CRs according to the KOL. Amazing If this get to the first line this is a potential functional cure for the majority of AL Amyloidosis patients. No need for chronic treatment less side effects and no slow deterioration of the organs" [X Link](https://x.com/BiotechPort/status/1997846252591907013) 2025-12-08T01:50Z 3619 followers, 4977 engagements "$KYMR is a $9B company with open label non controlled Ph1b data" [X Link](https://x.com/BiotechPort/status/1998046872653676834) 2025-12-08T15:07Z 3619 followers, 9718 engagements "$PRAX Chuck McCullogh independent statistician professor and Marcio ($PRAX CEO) are currently giving their takes on the essential tremor trial (HCW call). The changes to the study analysis was done before the data was locked so there is no bias and everything was kosher. The measurements were stat_sig at all times the data was measured in this trials. Both on the original and the changed design. All were stat_sig. The pV on the primary end point measured had X zeros (check me on that but this is what I heard) after the zero. Even if you run it on the original time end point it was still" [X Link](https://x.com/BiotechPort/status/1993028138507329752) 2025-11-24T18:45Z 3606 followers, 4795 engagements "I actually like Shkreli although I am far from agreeing with him on many points. He at least has balls. Which is not something I can say about many in our business. And laughing about someone blowing up is a very bad karma. Markets are round and have a shape of a suitcase. eventually it will meet you on one of the corners" [X Link](https://x.com/BiotechPort/status/1996730937636171903) 2025-12-04T23:58Z 3617 followers, 73.8K engagements "@Sanctuary_Bio The bispecifics are half of the efficacy (till now at least) nasty safety profile and chronic treatment. I am not sure anyone is seriously developing bispecifics in this indication. $IMMX should be approved next year" [X Link](https://x.com/BiotechPort/status/1997814484577259894) 2025-12-07T23:44Z 3620 followers, 1131 engagements "$TERN $IMMX Oral presentations at ASH" [X Link](https://x.com/BiotechPort/status/1985350110138572921) 2025-11-03T14:15Z 3620 followers, 3438 engagements "@Sanctuary_Bio $IMMX still looks better to me. Bispecific needs XX cycles monthly injections. Also it is not clear to me if AbbVie is pushing for approval in rr AL. Will be interesting to compare the safety" [X Link](https://x.com/BiotechPort/status/1997823509301760470) 2025-12-08T00:20Z 3619 followers, 1016 engagements "$WVE I am happy it is running. Let the Bulls run. Good for everyone. But no one explained me as of now how is a drug that reduces more fat in % than GLP-1 at 12w and had roughly the same lean mass effect as placebo did not reduce the total weight vs. placebo (actually I think it increased weight vs. placebo). "Muscle is more dense" does not explain it. First the difference in dancetty is XX% only and second placebo had very similar effect on muscle as the drug" [X Link](https://x.com/BiotechPort/status/1998170061660373421) 2025-12-08T23:17Z 3619 followers, 9819 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@BiotechPort FBCCFBCC posts on X about $immx, the first, $prax, at least the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.
Social category influence stocks X%
Social topic influence $immx #5, the first 10%, $prax 10%, at least 10%, $kymr 5%, $9b 5%, ceo 5%, the original 5%, business 5%, $capr X%
Top accounts mentioned or mentioned by @deepsouthdoctor @sanctuarybio @monaco_biotech @ciubsandwich070 @sanctuary_bio
Top assets mentioned Praxis Precision Medicines, Inc. Common Stock (PRAX) Kymera Therapeutics, Inc. Common Stock (KYMR) Terns Pharmaceuticals, Inc. Common Stock (TERN) AbbVie Inc (ABBV) Wave Life Sciences Ltd. Ordinary Shares (WVE)
Top posts by engagements in the last XX hours
"$IMMX It is possible we are seeing emergence of a functional cure for this nasty sever disease. Sure first it will go for the r/r patients but whoever will buy them out can move to the first. Patients can be cure directly after the diagnosis without the need of taking chronic drugs for years and preventing any continuation of slow deterioration of the organs. Also just secured a nice pipe. Supper cheap here. $150MM EV"
X Link 2025-12-07T23:28Z 3619 followers, 5279 engagements
"$IMMX "One and done treatment" according to the KOL. CRS Gr 1-2 (majority Gr1) 1d duration. No Neurological side effects. Some patients are in CR more than 12m The X in VGPR are on their way to get to CRs according to the KOL. Amazing If this get to the first line this is a potential functional cure for the majority of AL Amyloidosis patients. No need for chronic treatment less side effects and no slow deterioration of the organs"
X Link 2025-12-08T01:50Z 3619 followers, 4977 engagements
"$KYMR is a $9B company with open label non controlled Ph1b data"
X Link 2025-12-08T15:07Z 3619 followers, 9718 engagements
"$PRAX Chuck McCullogh independent statistician professor and Marcio ($PRAX CEO) are currently giving their takes on the essential tremor trial (HCW call). The changes to the study analysis was done before the data was locked so there is no bias and everything was kosher. The measurements were stat_sig at all times the data was measured in this trials. Both on the original and the changed design. All were stat_sig. The pV on the primary end point measured had X zeros (check me on that but this is what I heard) after the zero. Even if you run it on the original time end point it was still"
X Link 2025-11-24T18:45Z 3606 followers, 4795 engagements
"I actually like Shkreli although I am far from agreeing with him on many points. He at least has balls. Which is not something I can say about many in our business. And laughing about someone blowing up is a very bad karma. Markets are round and have a shape of a suitcase. eventually it will meet you on one of the corners"
X Link 2025-12-04T23:58Z 3617 followers, 73.8K engagements
"@Sanctuary_Bio The bispecifics are half of the efficacy (till now at least) nasty safety profile and chronic treatment. I am not sure anyone is seriously developing bispecifics in this indication. $IMMX should be approved next year"
X Link 2025-12-07T23:44Z 3620 followers, 1131 engagements
"$TERN $IMMX Oral presentations at ASH"
X Link 2025-11-03T14:15Z 3620 followers, 3438 engagements
"@Sanctuary_Bio $IMMX still looks better to me. Bispecific needs XX cycles monthly injections. Also it is not clear to me if AbbVie is pushing for approval in rr AL. Will be interesting to compare the safety"
X Link 2025-12-08T00:20Z 3619 followers, 1016 engagements
"$WVE I am happy it is running. Let the Bulls run. Good for everyone. But no one explained me as of now how is a drug that reduces more fat in % than GLP-1 at 12w and had roughly the same lean mass effect as placebo did not reduce the total weight vs. placebo (actually I think it increased weight vs. placebo). "Muscle is more dense" does not explain it. First the difference in dancetty is XX% only and second placebo had very similar effect on muscle as the drug"
X Link 2025-12-08T23:17Z 3619 followers, 9819 engagements
/creator/twitter::BiotechPort